Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report). The associated price target remains the same with $41.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Robert Burns has given his Buy rating due to a combination of factors that highlight the promising potential of Bicara Therapeutics Inc.’s lead candidate, ficerafusp alfa. The updated clinical results from the ongoing Phase 1/1b study, presented at ASCO 2025, demonstrate a notably high overall response rate (ORR) and complete response (CR) rate when combined with Keytruda in treating first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. These results surpass those observed in similar patient populations treated with Keytruda alone or with chemotherapy, as seen in the Phase 3 KEYNOTE-048 trial.
Moreover, the combination therapy has shown impressive median progression-free survival (mPFS) and median overall survival (mOS) metrics, which are significantly better than the typical outcomes for patients treated with Keytruda alone. This enhanced survival data, particularly the two-year survival rate, strengthens the case for ficerafusp alfa’s efficacy. Additionally, the analyst emphasizes that only risk-adjusted revenues for this candidate in the specified indication are included, reinforcing the conservative yet optimistic outlook. Consequently, the Buy rating is reiterated with a 12-month price target of $41.